Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial

作者：Ying Cheng, Yun Fan, Yanqiu Zhao, Dingzhi Huang, Xingya Li, Peng Zhang, Mafei Kang, Nong Yang, Diansheng Zhong, Zhen Wang, Yan Yu, Yu Zhang, Jun Zhao, Tai Qin, Chenqi Chen, Shiangjiin Leaw, Wenjuan Zheng, Yong Song · 发表于：Journal of Thoracic Oncology · 年份：2024 · DOI：10.1016/j.jtho.2024.03.008 · 被引用次数：146 · 研究领域：Lung Cancer Research Studies、PARP inhibition in cancer therapy、Neutropenia and Cancer Infections